Transdermal clonidine for smoking cessation: A double-blind randomized dose-response study

Raymond Niaura, Richard A. Brown, Michael G. Goldstein, Joseph K. Murphy, David Brian Abrams

Research output: Contribution to journalArticle

Abstract

A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers (N = 72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19% vs. 57%, respectively, p = .007). Blood clonidine concentration interacted with nicotine dependence (p <.05): High-dependence smokers who achieved higher blood clonidine concentrations survived longer before smoking a cigarette after quitting, as compared with high-dependence smokers who achieved lower blood levels. Changes from baseline in heart rate, blood pressure, appetite, irritability, and anxiety were inversely associated with blood clonidine concentrations.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalExperimental and Clinical Psychopharmacology
Volume4
Issue number3
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Clonidine
Smoking Cessation
Placebos
Tobacco Use Disorder
Appetite
Nicotine
Anxiety
Heart Rate
Smoking
Blood Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Experimental and Cognitive Psychology

Cite this

Transdermal clonidine for smoking cessation : A double-blind randomized dose-response study. / Niaura, Raymond; Brown, Richard A.; Goldstein, Michael G.; Murphy, Joseph K.; Abrams, David Brian.

In: Experimental and Clinical Psychopharmacology, Vol. 4, No. 3, 1996, p. 285-291.

Research output: Contribution to journalArticle

Niaura, Raymond ; Brown, Richard A. ; Goldstein, Michael G. ; Murphy, Joseph K. ; Abrams, David Brian. / Transdermal clonidine for smoking cessation : A double-blind randomized dose-response study. In: Experimental and Clinical Psychopharmacology. 1996 ; Vol. 4, No. 3. pp. 285-291.
@article{cea9fc1433c74df5972bd66c69c9186b,
title = "Transdermal clonidine for smoking cessation: A double-blind randomized dose-response study",
abstract = "A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers (N = 72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19{\%} vs. 57{\%}, respectively, p = .007). Blood clonidine concentration interacted with nicotine dependence (p <.05): High-dependence smokers who achieved higher blood clonidine concentrations survived longer before smoking a cigarette after quitting, as compared with high-dependence smokers who achieved lower blood levels. Changes from baseline in heart rate, blood pressure, appetite, irritability, and anxiety were inversely associated with blood clonidine concentrations.",
author = "Raymond Niaura and Brown, {Richard A.} and Goldstein, {Michael G.} and Murphy, {Joseph K.} and Abrams, {David Brian}",
year = "1996",
doi = "10.1037//1064-1297.4.3.285",
language = "English (US)",
volume = "4",
pages = "285--291",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "3",

}

TY - JOUR

T1 - Transdermal clonidine for smoking cessation

T2 - A double-blind randomized dose-response study

AU - Niaura, Raymond

AU - Brown, Richard A.

AU - Goldstein, Michael G.

AU - Murphy, Joseph K.

AU - Abrams, David Brian

PY - 1996

Y1 - 1996

N2 - A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers (N = 72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19% vs. 57%, respectively, p = .007). Blood clonidine concentration interacted with nicotine dependence (p <.05): High-dependence smokers who achieved higher blood clonidine concentrations survived longer before smoking a cigarette after quitting, as compared with high-dependence smokers who achieved lower blood levels. Changes from baseline in heart rate, blood pressure, appetite, irritability, and anxiety were inversely associated with blood clonidine concentrations.

AB - A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers (N = 72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19% vs. 57%, respectively, p = .007). Blood clonidine concentration interacted with nicotine dependence (p <.05): High-dependence smokers who achieved higher blood clonidine concentrations survived longer before smoking a cigarette after quitting, as compared with high-dependence smokers who achieved lower blood levels. Changes from baseline in heart rate, blood pressure, appetite, irritability, and anxiety were inversely associated with blood clonidine concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0029838506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029838506&partnerID=8YFLogxK

U2 - 10.1037//1064-1297.4.3.285

DO - 10.1037//1064-1297.4.3.285

M3 - Article

AN - SCOPUS:0029838506

VL - 4

SP - 285

EP - 291

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 3

ER -